The initial success of Sildenafil undeniably transformed the drug landscape, but betting in companies strongly reliant on generic versions presents a uncertain picture. Although early earnings were impressive, the end of patents and the appearance of discounted alternatives have weakened sales. Therefore, a thorough analysis of present income sourc